Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03175224 · ClinicalTrials.gov registry record · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A Phase 2 study of Lung Cancer and Gastric Cancer, sponsored by Apollomics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 497
- Enrollment target
- 20
- Study locations
NCT03175224: Recruiting Phase 2 study of Lung Cancer and Gastric Cancer, sponsored by Apollomics.
NCT03175224 is a Phase 2 study of Lung Cancer and Gastric Cancer that is actively recruiting participants, run by Apollomics. The registered enrollment target is 497 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03175224, a Phase 2 study of Lung Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Apollomics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 497 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)
Primary Outcome
Anti-tumor activity per RECIST v1.1, RANO criteria for CNS tumors, or relevant evaluation criteria per tumor type.
Conditions Studied
Interventions
- DRUG APL-101 Oral Capsules
Study Locations (20)
Other
- St Vincents Hospital Melbourne - Melbourne
- Cross Cancer Institute - Edmonton
- McGill University Health Center - Research Institute - Montreal
- Princess Margaret Hospital - Toronto
- Cancer Care Manitoba - Winnipeg
- CHRU de Brest - Hôpital Morvan - Brest
- Centre Leon Berard - Lyon
- Centre d'Essais Precoces en Cancerologie de Marseille - Marseille
- Hopital Bichat - Claude Bernard - AP-HP - Paris
- Gustave Roussy - Villejuif
- Orszagos Koranyi Pulmonologiai Intezet - Budapest
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz - Tatabánya
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola - Bologna
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - Meldola
California
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute - Los Angeles
Florida
- Moffitt - Tampa
Massachusetts
- Dana Farber Cancer Institute - Boston
North Carolina
- University of North Carolina - Chapel Hill
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2017-09-27 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
What NCT03175224 shows while recruiting
NCT03175224 is an interventional study that assigns participants to a tested intervention. The registered 497 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (47% lower).
The record links to 10 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which APL-101 Oral Capsules is the first listed.
NCT03175224 names 20 study sites across 7 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03175224 about?
NCT03175224 is a clinical study titled "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors". To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w...
What is the current status of trial NCT03175224?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 497 participants. The study started on 2017-09-27. Estimated completion is 2026-11-30.
What conditions does trial NCT03175224 study?
This clinical trial studies the following conditions: Lung Cancer, Gastric Cancer, Solid Tumors, Advanced Cancer, Glioblastoma Multiforme.
What interventions are being tested in trial NCT03175224?
The interventions under investigation include: APL-101 Oral Capsules (DRUG).
Who is sponsoring clinical trial NCT03175224?
This trial is sponsored by Apollomics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03175224 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03175224's enrollment target sits among peer trials
497 73rd of 409 higher than 337 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
- NCT05766670 · 497 participants · Phase 3
Intramedullary Calcium Sulfate Antibiotic Depot
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI